Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research note issued to investors on Thursday.

A number of other research firms also recently commented on MCRB. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Trading Down 3.9 %

NASDAQ MCRB opened at $0.74 on Thursday. The business’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.84. The company has a market capitalization of $125.49 million, a PE ratio of -3.20 and a beta of 2.11. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently modified their holdings of the stock. FMR LLC grew its stake in shares of Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after buying an additional 140,096 shares in the last quarter. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after buying an additional 788,762 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Seres Therapeutics by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after buying an additional 121,793 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 543,469 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 117,107 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.